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We have studied platelet function in 10 patients with severe liver cirrhosis, compared to healthy subjects. 
Using washed platelets, we have investigated the molecular mechanism underlying the defect in platelet ag- 
gregation frequently observed in these patients. We have found that platelets from cirrhotic patients have 
a reduced responsiveness to thrombin and collagen in terms of aggregation, and receptor-dependent activa- 
tion of phospholipase C, 4 and cyclooxygenase/thromboxane synthetase. We thus suggest hat this impair- 
ment in transmembrane signalling is responsible for the defective platelet function observed in cirrhosis. 
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1. INTRODUCTION 
Liver cirrhosis is commonly associated with 
hemorrhagic disorders. A number of factors may 
contribute to the bleeding tendency that constitutes 
one of the main causes of death in this condition 
[ 11. One of these factors is defective platelet 
response to various agonists, and the degree of this 
impairment has been related to the severity of liver 
disease [2]. However, it is still unclear whether the 
reduced platelet responsiveness is due to a primary 
defect in platelets or is due to abnormal circulating 
factors specifically related to cirrhosis. In order to 
answer this question, and to focus our investiga- 
tion solely on platelet function, we used washed 
platelets, thus avoiding any interference by plas- 
matic alterations. We examined platelet aggrega- 
tion and the underlying molecular mechanism in 
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response to exogenous thrombin and collagen, 
which are two major platelet physiological 
agonists. 
The action of these agonists on human platelets 
is associated with shape change, aggregation and 
release reaction, which occur in parallel with 
fibrinogen receptor expression, formation of ino- 
sitol polyphosphates and 1,2-diacyglycerol, its 
phosphorylated product phosphatidic acid, forma- 
tion of arachidonic acid metabolites, and phospho- 
rylation of specific proteins [3,4]. Sequential 
activation of phospholipase C and phospholipase 
AZ leads to the production of arachidonic acid and 
its metabolites (endoperoxides and thromboxane) 
which further amplify the response through 
receptor-mediated activation of phospholipase C. 
In this study we have monitored agonist-induced 
platelet aggregation, phospholipase C and AZ ac- 
tivation, and thromboxane Bz formation in washed 
platelets from healthy subjects and cirrhotic pa- 
tients in order to define the molecular mechanism 
underlying the platelet defect in cirrhosis. 
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2. EXPERIMENTAL Table 1 
Ten cirrhotic patients, 7 males and 3 females, 
were included in this study. The aetiology of cir- 
rhosis was as follows: chronic alcohol abuse in 6 
cases; chronic hepatitis B virus infection in 3 cases; 
unknown origin in 1 case. The age range of the pa- 
tients was 35-63, mean age 53. Diagnosis of liver 
disease was based on clinical and biochemical 
features and liver biopsy. All patients belonged to 
class B or C, according to a modified Child 
classification [5]. Neither patients nor healthy con- 
trols had taken any medication known to interfere 
with platelet function for at least 2 weeks prior to 
the study. 
Platelet responses to thrombin and collagen in cirrhotic 
patients and healthy subjects 
Preparation of washed platelets, labelling and 
platelet aggregation determinations were per- 
formed as described [6,7]. Formation of [1-14C] 
phosphatidic acid, [l-‘4C]arachidonic acid, and 
12-hydroxy[l-‘“Clheptadecatrienoic acid from 
platelets prelabelled with [I -‘4C]arachidonic acid 
was measured by separating these compounds by 
thin-layer chromatography [7]. Thromboxane B2 
formation was measured by radioimmunoassay 
ta. 
Materials: Thrombin (human) and collagen were 
from Sigma, USA. [l-‘4C]Arachidonic acid was 
from Amersham, USA. All other reagents were of 
analytical grade. 
3. RESULTS AND DISCUSSION 
Table 1 shows that aggregation induced by 
thrombin (0.3 units/ml) or collagen (20 yg/ml), in 
washed platelets obtained from cirrhotic patients 
with severe liver disease, is greatly reduced com- 
pared to healthy subjects. [l-‘4C]Phosphatidic acid 
formation is also impaired in cirrhotic patients, in 
response to thrombin and collagen. This might 
represent a defect in receptor-dependent phospho- 
lipase C activation in cirrhosis. Although we know 
that measurement of phosphatidic acid formation 
is only an indirect way to investigate phospholipase 
C activation, we have chosen this method in order 
to obtain the greatest amount of information on 
each patient; as a matter of fact, common throm- 
bocytopenia of cirrhotic patients is a major 
obstacle in obtaining an adequate number of 
platelets to perform a detailed study on [3H]ino- 
sitol phosphate formation. 
Thrombin Collagen 
Patients Controls Patients Controls 
Aggregation 22+ 3 85k 5 12-t 2 67+ 4 
[I-‘“C]PA 165-+ 8 369+ 11 135-t 3 260+ 5 
[I-‘4C]AA 148 f 5 1355 + 10 118 -t 4 357 f 8 
[l-‘4C]HHT 187 k 15 778 k 80 120 k 13 387 I? 41 
TxBz (RIA) 22+ 6 115-t 12 55 f 4 112* 7 
Samples (0.5 ml) of washed platelets that had been pre- 
labelled with [l-‘4C]arachidonic acid were incubated at 
a final concentration of 4 x 108/ml in aggregometer 
tubes at 37°C. Thrombin (0.3 units/ml) or collagen 
(20pg/ml) were then added and the reaction was 
stopped 2 min after the addition of the agonists. Light 
transmission was recorded throughout the experiment 
and displayed on a chart recorder. Platelet aggregation 
is expressed as % increase in light transmission. Phos- 
phatidic acid (PA), arachidonic acid (AA), and 
12-hydroxyheptadecatrienoic acid (HHT) were extracted 
by adding 1.88 ml of chloroform/methanol (100 : 200, 
v/v). These compounds were then separated by thin- 
layer chromatography, as described [7]. Data are re- 
presented as % increase over basal (unstimulated) 
values. Basal values of representative experiments were: 
[I-“C]PA, 157 k 17 cpm; [I-“C]AA, 1671 + 85 cpm; 
[I-“C]HHT, 125 k 18 cpm (means f SE of quadrupli- 
cate samples). TxB2 was extracted and measured by 
radioimmunoassay (RIA), as described in [8]; data are 
expressed as ng/ml. All the results are shown as means 
k SE from 10 separate experiments (i.e., one cirrhotic 
patient and one healthy subject in each experiment) each 
performed in quadruplicate 
Agonist-induced activation of phospholipase AZ 
is also greatly impaired in cirrhosis, as reflected by 
decreased liberation of [ 1 -‘4C]arachidonic acid in 
cirrhotic patients compared to healthy controls. It 
is worth noting that in these experiments labelling 
with [l-‘4C]arachidonic acid was performed in 
washed platelets, where the number of platelets 
derived from cirrhotic patients and healthy 
volunteers was adjusted to the same concentration. 
By so doing, we have been able to determine that 
platelets of both groups incorporate approximately 
the same amount of [l-‘4C]arachidonic acid. 
Therefore, we believe that the observed impair- 
ment in agonist-induced arachidonic acid libera- 
tion is actually due to a defect in the 
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transmembrane signalling machinery, specifically 
related to the severity of liver disease. 
Consistently, production of cyclooxygenase/ 
thromboxane synthetase metabolites is also im- 
paired in cirrhotic patients, as shown in table 1. In 
this case we have measured 12-hydroxy[l-‘4C]hep- 
tadecatrienoic acid by thin-layer chromatography 
analysis, and thromboxane B2 by radioimmuno- 
assay. The consistency of the results leads us to 
think that a reduced production of cyclooxy- 
genase/thromboxane synthetase actually occurs in 
platelets from cirrhotic patients stimulated by 
thrombin or collagen. 
We think that the impairment in transmembrane 
signalling that we have observed in platelets from 
cirrhotic patients is responsible for the reduced 
platelet responsiveness to agonists in terms of ag- 
gregation. We suggest that changes in the lipid 
composition and in the fluidity of platelet plasma 
membrane in cirrhosis are responsible for this im- 
pairment. Several findings support this hypothesis: 
it has been demonstrated that alterations in plasma 
membrane phospholipid composition, similar to 
those observed in cirrhosis, greatly reduce phos- 
pholipase C activation [9]. A decrease in platelet 
plasma membrane fluidity reduces thrombin- 
stimulated thromboxane synthesis [lo], and it has 
been demonstrated that patients with liver disease 
have a lower membrane fluidity [ 111. 
In conclusion, we propose that platelet impair- 
ment in cirrhosis is a primary platelet defect that 
involves a reduced responsiveness of the enzymes 
related to agonist-stimulated transmembrane 
signalling, i.e., phospholipase C, AZ, and cycloox- 
ygenase/thromboxane synthetase. 
ACKNOWLEDGEMENT 
This study has been supported in part by a grant 
of the Italian Association for Cancer Research 













Garceau, A.J. and Chalmers, T.C. (1963) New 
Engl. J. Med. 268, 469-473. 
Owen, J.S., Hutton, R.A., Day, R.C., 
Bruckdorfer, R.K. and McIntyre, N. (1981) J. 
Lipid Res. 22, 423-429. 
Lapetina, E.G. (1987) in: Phosphoinositides and 
Receptor Mechanism (Putney, J.W. jr ed.) pp. 
271-286, A.R. Liss, New York. 
Nishizuka, Y. (1983) Phil. Trans. R. Sot. Lond. 
(Biol) 302, 101-l 12. 
Laffi, G., La Villa, G., Pinzani, M., Ciabattoni, 
G., Patrignani, P., Mannelli, M., Cominelli, F. 
and Gentilini, P. (1986) Gastroenterology 30, 
274-282. 
Ruggiero, M. and Lapetina, E.G. (1986) Proc. 
Natl. Acad. Sci. USA 83, 3456-3459. 
Ruggiero, M., Zimmerman, T.P. and Lapetina, 
E.G. (1985) Biochem. Biophys. Res. Commun. 
131, 620-627. 
Laffi, G., Cominelli, F., La Villa, G., Fedi, S., 
Pinzani, M., Meacci, E. and Gentilini, P. (1987) in: 
Advances in Prostaglandin, Thromboxane, and 
Leukotriene Research (Samuelsson, B. et al. eds) 
vol. 17, pp. 366-369, Raven Press, New York. 
Irvine, R.F., Letcher, A.J. and Dawson, R.M.C. 
(1984) Biochem. J. 218, 177-185. 
Moscat, J., Perez, P., Garilanes, F.G., Acin, F., 
Schuller, A. and Municio, A.M. (1986) Thromb. 
Res. 44, 197-205. 
Schuller, A., Solis-Herruzo, J.A., Moscat, J., 
Fernandez-Checa, J.C. and Municio, A.M. (1986) 
Hepatology 6, 714-717. 
219 
